(Q42977474)

12 November 2017

Dapagliflozin, an SGLT2 inhibitor, for diabetes (English)

1 reference

12 November 2017

1

Markolf Hanefeld

1 reference

12 November 2017

Thomas Forst

2

1 reference

PubMed ID

20609956

12 November 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

375

1 reference

12 November 2017

9733

1 reference

12 November 2017

2196-2198

1 reference

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

1 reference

7 January 2021

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Cytokine secretion is impaired in women with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Urologic complications of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960749-0

7 January 2021

10.1016/S0140-6736(10)60749-0

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

20609956